4Moving biotech obtained Belgium's agency approval to initiate the LASARE phase I clinical study for 4P004, a first-in-class novel candidate to treat osteoarthritis.​

We are proud of this agency decision as it supports the efforts conducted by our team, showing that 4P004 has a unique triple effect: anti-pain, anti-inflammatory, cartilage protection/regeneration.​

For more information, please feel free to contact us

‍

‍